| Marian Flores Manankil, MD | |
|
510 S 4th St, Gadsden, AL 35901-5217 | |
| (256) 438-5008 | |
| (256) 467-4009 |
| Full Name | Marian Flores Manankil |
|---|---|
| Gender | Female |
| Speciality | Cardiac Electrophysiology |
| Experience | 21 Years |
| Location | 510 S 4th St, Gadsden, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124276951 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverview Regional Medical Center | Gadsden, AL | Hospital |
| Dekalb Regional Medical Center | Fort payne, AL | Hospital |
| Gadsden Regional Medical Center | Gadsden, AL | Hospital |
| Grandview Medical Center | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Medical Clinic Llc | 5597038729 | 2 |
| Prime Healthcare Services Gadsden Physician Management Llc | 7113231945 | 19 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today an exclusive distribution agreement with CapsoVision for their CapsoCam Plus Capsule Endoscopy line of products.
A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by Lukas Kenner of MedUni Vienna has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.
Arbor Pharmaceuticals announced today that it has filed its first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The recently filed product has been granted an Orphan designation by the FDA which provides seven years of market exclusivity.
› Verified 5 days ago
| Entity Name | Prime Healthcare Services Gadsden Physician Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356731467 PECOS PAC ID: 7113231945 Enrollment ID: O20150806011161 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today an exclusive distribution agreement with CapsoVision for their CapsoCam Plus Capsule Endoscopy line of products.
A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by Lukas Kenner of MedUni Vienna has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.
Arbor Pharmaceuticals announced today that it has filed its first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The recently filed product has been granted an Orphan designation by the FDA which provides seven years of market exclusivity.
› Verified 5 days ago
| Entity Name | Integrated Medical Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093237125 PECOS PAC ID: 5597038729 Enrollment ID: O20170908002516 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today an exclusive distribution agreement with CapsoVision for their CapsoCam Plus Capsule Endoscopy line of products.
A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by Lukas Kenner of MedUni Vienna has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.
Arbor Pharmaceuticals announced today that it has filed its first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The recently filed product has been granted an Orphan designation by the FDA which provides seven years of market exclusivity.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marian Flores Manankil, MD 510 S 4th St, Gadsden, AL 35901-5217 Ph: (256) 438-5008 | Marian Flores Manankil, MD 510 S 4th St, Gadsden, AL 35901-5217 Ph: (256) 438-5008 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today an exclusive distribution agreement with CapsoVision for their CapsoCam Plus Capsule Endoscopy line of products.
A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by Lukas Kenner of MedUni Vienna has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.
Arbor Pharmaceuticals announced today that it has filed its first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The recently filed product has been granted an Orphan designation by the FDA which provides seven years of market exclusivity.
› Verified 5 days ago
Dr. Peter Ming Szeto, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1102 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-9924 Fax: 256-492-9965 | |
Dr. James N Wallace, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 512 S 4th St, Gadsden, AL 35901 Phone: 256-547-2255 Fax: 256-547-2257 | |
Jed L Kaplan, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 900 Goodyear Ave, Suite A, Gadsden, AL 35903 Phone: 256-492-3220 Fax: 256-492-3759 | |
Dr. George Bruce Head Iii, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1102 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-9924 Fax: 256-492-9965 | |
Dr. Muhammad Tariq, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1411 Piedmont Cutoff, Gadsden, AL 35903 Phone: 256-492-0131 | |
Sabrina Nicole Morgan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 851 Goodyear Ave, Gadsden, AL 35903 Phone: 800-780-4146 Fax: 256-494-5063 | |
Vijayaprasad Tummala, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 Goodyear Ave, Suite A, Gadsden, AL 35903 Phone: 256-492-3220 Fax: 256-492-3759 |